Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: JPetroInc, freegriff
Search This Board: 
Last Post: 5/23/2022 9:26:31 PM - Followers: 650 - Board type: Free - Posts Today: 4

Amarantus BioScience Holdings develops and maintains interests in its biotechnology focused subsidiary companies briefly described below:

1. Elto Pharma, Inc. 50.1%-owned by Amarantus in partnership with Psychogenics. Elto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for the treatment of Parkinson's disease levodopa-induced dyskinesia, Alzheimer’s aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. Dr. Paula Trzepacz, formerly Senior Medical Fellow in Neurosciences drug development at Eli Lilly, serves as Elto Pharma’s Chief Medical Advisor. The combined therapeutic market for Parkinson’s Alzheimer’s and ADHD treated by eltoprazine is estimated to be over $30B.

2. Cutanogen Corporation: 90.1% owned by Amarantus. Cutanogen Corporation is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriner’s Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. Dr. Richard Kagan, formerly Chief of Staff at the Shriners Burn Hospital in Cincinnati and past President of the American Burn Association, serves as Chief Medical Advisor for Cutanogen Corporation. The market for skin-grafting related disorders is estimated at $5B.

3. MANF Therapeutics, Inc.: 100% owned by Amarantus. MANF Therapeutics Inc. owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (“MANF”). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram’s Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinson’s disease. MANF was discovered by the Company’s Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS’ proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. Dr. John Commissiong, formerly Head of the Neurotrophic Factors Group at the National Institute of Neurological Disease and Stroke, serves as Chief Scientific Advisor to MANF Therapeutics. The combined market for indications treated by MANF exceeds $50B.

4. Security interests in Todos Medical ($TOMDF) and Theralink Technologies ($OBMP) (f/k/a Avant Diagnostics, Inc.), owning 78 million shares of Todos Medical, and 31.5% of Theralink prior to completion of corporate restructuring of Theralink Technologies, which is in progress. The restructuring will likely result in a dilution of the Company’s ownership.

5. Security Interests in Hempori, Inc. Amarantus has a 51% interest in Hempori, a revenue-generating distributor of CBD and other Cannabis related products in Texas.
              Share Structure and Security Details (as of 3/19/2022)                       Mesencephalic Astrocyte-derived Neurotrophic Factor (MANF)                                  Experienced Management                                    

MANF was discovered by Chief Scientific Officer John Commissiong is emerging as one of the greatest scientific discoveries in modern biotechnology with preclinical research indicating therapeutic potential in dozens of indications, with more potential applications being discovered through growing research interest each year. A brief review of the scientific literature is available at the following link: https://www.semanticscholar.org/search?q=mesencephalic%20astrocyte-derived%20neurotrophic%20factor&sort=relevance
Potential Indications served by AMBS Assets
 Parkinson's Disease (PD)
 Amyotrophic Lateral Sclerosis (ALS) - Lou Gehrig's Disease 
 Ischemic Heart Disease
 Alzheimer's Disease (AD)
 Huntington's Disease
 Traumatic Brain Injury/ Chronic Traumatic Encephalopathy (TBI/CTE)
ischaemic stroke
Bipolar Disorder
maintaining circadian plasticity of neurons
Umbilical Cord Mesenchymal Stem Cells for treating Spinal Cord Injury 
Charcot-Marie-Tooth disease (CMT)
cancer immunotherapy
Retinitis Pigmentosa (RP); and,
other Inherited Retinal Disorders
Multiple Sclerosis Experimental autoimmune encephalomyelitis
Control of Energy Homeostasis
Liver Damage
Heart Attack 
Bacterial Myocarditis
Age-related macular degeneration
MANF in Acetaminophen (APAP)-induced liver injury (AILI) 
Post-Operative Delirium via Inhibiting Inflammation and Microglia Activation
Sporadic Retinal Disorders
Other degenerative disorders and retinal injury
Wolfram's Syndrome
Diabetes Type-1
Diabetes Type-2
type 2 diabetes mellitus
alcoholic pancreatitis
Diagnosis of Parkinson's Disease
Assays for diagnosis and therapeutics
47 Protein Biomarkers for Neurodegenerative Diseases
Assays for Amyotrophic Lateral Sclerosis (ALS) and ALS-like disorders
Diagnosis of Alzheimer's Disease
Alzheimer's Disease (AD)
Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID)
Attention Deficit Hyperactivity Disorder (ADHD)
Lipidomics Assay
Exosomes Assay
Four additional Assays
Congenital Hairy Nevus
Type 3 and 4 intractable severe burns
MSPrecise Diagnostic for Multiple Sclerosis (MS)
Neurosarcoid Diagnostic Assay
Neuromeylitis optica Diagnostic Assay
Para neoplastic Disease Diagnostic Assay
Amyotrophic Lateral Sclerosis (ALS) Diognostic Assay

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS News: Amended Statement of Beneficial Ownership (sc 13d/a) 04/18/2022 12:18:50 PM
AMBS News: Amended Statement of Beneficial Ownership (sc 13d/a) 04/18/2022 12:14:29 PM
#130199   absolutely no worries here...!!! JPetroInc 05/23/22 09:26:31 PM
#130198   Would you like to explain what that means. leslunier 05/23/22 05:58:32 PM
#130197   Due for a bounce here? MattyTrader 05/23/22 04:28:09 PM
#130196   Yes, Huffman is CEO. That's a legacy typo freegriff 05/23/22 07:40:40 AM
#130195   nothing new here - just the same old... JPetroInc 05/22/22 08:49:06 PM
#130194   Thought Huffman was ceo. Why is GC leslunier 05/22/22 02:34:55 PM
#130193   $AMBS Q122 10-Q published freegriff 05/22/22 04:25:02 AM
#130190   Two new publications on MANF last week: freegriff 05/21/22 09:37:28 PM
#130187   AMBS has been serial diluted since 2008 JPetroInc 05/18/22 02:39:13 PM
#130186   High volume last week, but not dilution...hmmmm freegriff 05/17/22 05:02:32 PM
#130185   potential 10,000 prospective novice and unsuspectiong shareholders who JPetroInc 05/12/22 10:11:49 PM
#130183   "I don't want anything to do with Gerald freegriff 05/11/22 04:03:27 PM
#130182   survive what...? win what...? make JPetroInc 05/11/22 07:58:59 AM
#130181   Same old same old from JP. We will freegriff 05/11/22 12:32:24 AM
#130180   AMBS MC = $1.47-Mil. as of 05/10 COB JPetroInc 05/10/22 10:05:05 PM
#130179   OK last week…..blah blah blah JPetroInc 05/10/22 09:12:11 AM
#130178   Ok last week we did see dilution, 17M freegriff 05/09/22 10:49:59 AM
#130177   MANF is the reason why I originally invested JPetroInc 05/07/22 07:54:45 PM
#130176   griff, please take the word bankruptcy out of JPetroInc 05/07/22 07:51:07 PM
#130175   Here was the last meaningful update from the freegriff 05/07/22 04:44:19 PM
#130174   Yes, despite your predictions of bankruptcy, AMBS will freegriff 05/07/22 04:25:23 PM
#130173   despite my predictions...? JPetroInc 05/07/22 10:31:24 AM
#130172   Fine as ever JP the price simply does freegriff 05/06/22 07:36:14 PM
#130171   hows that new (old) news workin for ya griff...? JPetroInc 05/06/22 05:42:53 PM
#130170   Ugh... JPetroInc 05/06/22 06:55:57 AM
#130169   Old news thugmuffin leslunier 05/05/22 04:51:55 PM
#130168   What do you think about the news ThugMuffin? freegriff 05/05/22 11:22:13 AM
#130167   $AMBS Amarantus Signs Non-Binding Term Sheet to Divest Thugmuffin 05/05/22 09:25:37 AM
#130165   Well we'll well, ZERO dilution AGAIN last week freegriff 05/02/22 11:16:03 AM
#130164   don't have too - this is most likely JPetroInc 04/30/22 09:35:31 PM
#130163   Why don't you wait for Monday when share freegriff 04/30/22 02:32:06 PM
#130162   this looks like a post PR 2.6-Mil. DILUTIVE DUMP... JPetroInc 04/30/22 10:24:03 AM
#130161   Les, I really appreciated the straight forward Stuville 04/28/22 06:56:09 AM
#130160   if this plan works AND Gerald Commissiong is JPetroInc 04/27/22 02:14:27 PM
#130159   Stu, sounds promising. Looks like AMBS finally got rid leslunier 04/27/22 09:00:34 AM
#130158   its pretty good move for AMBS - imho deexra 04/27/22 08:53:27 AM
#130157   News out! First PR from AMBS in Stuville 04/27/22 07:53:12 AM
#130156   AMBS has consistently diluted since FY08 incorporation JPetroInc 04/26/22 12:51:08 PM
#130155   Very interesting. NO DILUTION last week (or since freegriff 04/25/22 12:35:19 PM
#130154   that A/D line sure looks like its stuck JPetroInc 04/21/22 05:12:24 AM
#130153   So when did you sink your first 6 GreeseMonkey 04/21/22 02:38:22 AM
#130152   Please stop posting family pics on here. No GreeseMonkey 04/21/22 02:31:35 AM
#130151   I dunno Griff JPetroInc 04/20/22 08:02:24 PM
#130150   We will see if this is dumping, dilution freegriff 04/20/22 04:35:33 PM
#130149   welp Griff ... JPetroInc 04/20/22 04:25:57 PM
#130148   a lil AMBS business plan would help - JPetroInc 04/20/22 04:20:11 PM
#130147   I agree, but I think it will take freegriff 04/19/22 08:05:32 PM
#130146   As AMBS shareholders, I think we are entitled Stuville 04/19/22 06:02:06 PM
#130145   of course they're going to add more debt, freegriff 04/19/22 02:25:03 PM
#130144   they're just going to add more debt... JPetroInc 04/19/22 06:38:44 AM
Consent Preferences